Analyst Price Targets — IPSC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 13, 2026 12:24 pm | Daina Graybosch | Leerink Partners | $2.00 | $2.52 | StreetInsider | Leerink Partners Reiterates Market Perform Rating on Century Therapeutics (IPSC) |
| January 20, 2026 11:50 am | — | Piper Sandler | $4.00 | $2.17 | TheFly | Century Therapeutics price target raised to $4 from $2 at Piper Sandler |
| November 6, 2024 11:41 am | Mitchell Kapoor | H.C. Wainwright | $5.00 | $1.39 | StreetInsider | Century Therapeutics (IPSC) PT Lowered to $5 at H.C. Wainwright |
| April 12, 2024 7:02 am | Edward Tenthoff | Piper Sandler | $9.00 | $4.05 | StreetInsider | Century Therapeutics (IPSC) PT Lowered to $9 at Piper Sandler |
| January 5, 2023 9:48 pm | Edward Tenthoff | Piper Sandler | $14.00 | $4.84 | TheFly | Century Therapeutics price target lowered to $14 from $24 at Piper Sandler |
| December 27, 2022 5:35 am | Geulah Livshits | Chardan Capital | $19.00 | $5.67 | TheFly | Century Therapeutics initiated with a Buy at Chardan |
| November 14, 2022 6:24 am | — | H.C. Wainwright | $25.00 | $11.00 | Benzinga | HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $25 |
| April 29, 2022 5:38 am | — | Leerink Partners | $27.00 | $12.03 | Benzinga | SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $27 |
Latest News for IPSC
Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026 CNTY-813 preclinical data from oral presentation at ADA 2026 showed durable glucose control in vivo, immune evasion, and manufacturing success at clinical scale, advancing its potential as a functional cure for T1D Upcoming oral…
ALISO VIEJO, Calif.--(BUSINESS WIRE)--IHI Power Services Corp. (IPSC), a leading operator of power plants across the U.S., has a new name as it enters a new chapter. Effective today, IPSC officially becomes Kyuden Energy Partners Corporation, following the completion of its acquisition by Kyuden International Corporation (Kyuden International), a wholly owned subsidiary of Kyushu Electric Power Company—one of…
PHILADELPHIA, July 09, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced that its abstracts have been accepted for oral presentations at two upcoming scientific congresses:
PHILADELPHIA, June 08, 2026 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes (T1D), and cancer, today announced the presentation of new preclinical data from CNTY-813, Century's iPSC-derived islet replacement therapy engineered with Allo-Evasion™…
Advancing CNTY-813 as a potential functional cure in Type 1 Diabetes CNTY-813 iPSC-derived islet replacement therapy demonstrates durable in-vivo glucose control maintained for more than eight months in preclinical models Allo-Evasion 5. 0 maintains insulin secretion and maintained normoglycemia under allogeneic immune pressure in humanized mouse model without immunosuppression Phase 1 clinical manufacturing process…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IPSC.
U.S. House Trading
No House trades found for IPSC.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.